Toll Free: 1-888-928-9744

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H2 2016', provides an overview of the Premature Labor (Tocolysis) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
- The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects
- The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Premature Labor (Tocolysis) Overview 7 Therapeutics Development 8 Pipeline Products for Premature Labor (Tocolysis) - Overview 8 Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 9 Premature Labor (Tocolysis) - Therapeutics under Development by Companies 10 Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes 11 Premature Labor (Tocolysis) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Premature Labor (Tocolysis) - Products under Development by Companies 16 Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes 17 Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 18 AMAG Pharmaceuticals, Inc. 18 GlaxoSmithKline Plc 19 Juniper Pharmaceuticals, Inc. 20 Kissei Pharmaceutical Co., Ltd. 21 Lipocine Inc. 22 ObsEva SA 23 Premature Labor (Tocolysis) - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 32 bedoradrine sulfate - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 hydroxyprogesterone caproate - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 hydroxyprogesterone caproate - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 OBE-001 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 OBE-022 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 progesterone - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 retosiban - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule for Acute Inflammation and Premature Labor - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules for Premature Labor - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Premature Labor (Tocolysis) - Dormant Projects 46 Premature Labor (Tocolysis) - Discontinued Products 47 Premature Labor (Tocolysis) - Product Development Milestones 48 Featured News & Press Releases 48 Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor 48 Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 48 Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 49 Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women 50 Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301 50 Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena 51 Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection) 51 Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor 52 Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways 52 Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women 53 May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena 54 May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth 54 Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour 55 Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour 56 Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma's Makena 56 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 6
List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H2 2016 8 Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Comparative Analysis by Unknown Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals, Inc., H2 2016 18 Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2016 19 Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016 20 Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 21 Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H2 2016 22 Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Number of Products by Stage and Target, H2 2016 26 Number of Products by Stage and Mechanism of Action, H2 2016 28 Number of Products by Stage and Route of Administration, H2 2016 30 Number of Products by Stage and Molecule Type, H2 2016 31 Premature Labor (Tocolysis) - Dormant Projects, H2 2016 46 Premature Labor (Tocolysis) - Discontinued Products, H2 2016 47



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify